Farmas USA

GALE

Galena Biopharma Announces Settlement of Securities Class Action and Shareholder Derivative Lawsuits

http://finance.yahoo.com/news/galena-biopharma-announces-settlement-securities-120500832.html?soc_src=mediacontentstory&soc_trk=tw
The agreement in the securities action provides for a settlement payment to the class of $20,000,000, of which $16,700,000 will be paid by the Company's insurance carriers, and $3,300,000 will be paid by the Company through a combination of $2,300,000 in cash and $1,000,000 in shares of the Company's common stock. The shares shall constitute less than one percent of the total shares then outstanding.

The terms of the settlement for the derivative action include a payment of $15,000,000 in cash by the Company's insurance carriers, which the Company will use to fund the class action settlement, and cancellation of 1,200,000 director stock options. Galena has also agreed to adopt or continue its implementation of changes and additions to certain corporate governance policies, protocols and practices. In addition, the Company's insurance carriers agreed to pay $5,000,000 for plaintiff's attorneys' fees and costs, subject to Court approval.

Quiero pensar que dejamos atras el lateral 6,5-8 y que hoy tendremos algun tipo de rebote con la new de anoche.

Pero el sector debe acompañar o sino ...

NVAX

Espera, una demanda de esas que ha acabado rascando pasta a la compañia???? La primera que veo 

GALE

Ojo, que con Bankinter hay Farmas en las que los stop loss no están disponibles....desde la plataforma móvil , IPhone , IPad etc....😉, por lo demás funciona muy bien y la tarifa es 21,16$/19,44€ .

Welcome to the 57th ASH Annual Meeting & Exposition

December 5-8, 2015

Espero que tengamos al menos una jornada verde 

Parece que han llegado a un acuerdo para no ir a juicio, no? No sé a qué demanda se refiere, si es una de esas tan típicas que vemos y que nunca ocurre nada, o es otro tipo...

GALE

No dejo de mirar a las big pharmas si abren premarkets ... parece que la primera es GILD con +0,5% solo unos 1500 cromos.

Horizon Pharma (NASDAQ:HZNP) resumed with Underweight rating and $23 (14% upside) price target by Morgan Stanley.

Prima Biomed (NASDAQ:PBMD) initiated with Outperform rating and $6 (376% upside) price target by FBR Capital.

Bluebird bio (NASDAQ:BLUE) resumed with Buy rating and $121 (54% upside) price target by Roth Capital.

Barclays initiates coverage of six large caps: AbbVie (NYSE:ABBV) with an Equal Weight rating and $72 (28% upside) price target; Bristol-Myers Squibb (NYSE:BMY) with an Equal Weight rating and $70 (5% upside) price target; Johnson & Johnson (NYSE:JNJ) with an Overweight rating and $115 (14% upside) price target; Merck with an Overweight rating and a $66 (25% upside) price target; Eli Lilly (NYSE:LLY) with an Overweight rating and $95 (14% upside) price target and Pfizer (NYSE:PFE) with an Equal Weight rating and $34 (5% upside) price target.

GW Pharmaceuticals (NASDAQ:GWPH) resumed with Buy rating and $130 (51% upside) price target by Roth Capital.

ImmunoGen (NASDAQ:IMGN) resumed with Buy rating and $16 (24% upside) price target by Jefferies.

Myokardia (NASDAQ:MYOK) initiated with an Outperform rating and $22 (75% upside) price target by Wedbush and an Outperform rating and $18 (43% upside) price target by Credit Suisse.